News | Mammography | September 30, 2015

Volpara Showcases Breast Density Assessment and Analytics Tools at RSNA

Volpara, breast density fiber glandular density

September 30, 2015 — Volpara Solutions will be showcasing the latest updates on its breast density and quantitative breast imaging capabilities at booth (South Hall - 2377), including:

•    VolparaDensity – the latest version of VolparaDensity, the benchmark in breast density assessment and clinically proven versus sensitivity of mammography and risk of developing cancer. RSNA updates include configurable breast density scorecards, a high capability server and and the ability to route patient results by Volpara’s FDA cleared Volpara Density Grades (VDG), analogous to the BI-RADS density categories. 

•    VolparaAnalytics v1.2 – Featuring a re-designed user interface and reporting features, VolparaAnalytics v1.2 also delivers expanded breast imaging metrics to users, including new temporal analysis tools, additional tools to analyze patient positioning and patient-dose, and time between study acquisitions.

•    RSNA Presentations: Volpara and Volumetrics Related Research – The ability of volumetric breast density, patient-specific mammographic dose and volumetric breast imaging metrics to provide critical insight for optimal breast imaging workflow is the focus of numerous studies being presented at RSNA, including:

- Quantifying the potential masking risk of breast density in mammographic screening, Dr Stamatia V. Destounis, M.D. 

- Volumetric breast density a strong independent predictor of interval cancer risk, Dr Stamatia V. Destounis, M.D.

- Volumetric breast density and mean glandular dose estimated from digital breast tomosynthesis projections and digital mammograms, Prof Kwan Ng  

•    Volpara Solutions’ complete suite of quantitative breast imaging tools: built to enable personalized measurements of volumetric breast density, patient-specific dose, breast compression and other factors to help breast imaging centers maintain accuracy and consistent quality in breast screening.  

- VolparaDensity: VolparaDensity is used by radiologists to objectively assess density from digital mammograms to help doctors evaluate which women would benefit from additional screening.  Highly correlated to 3D breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR breast density categories.  To date, more than 7-million women have had their breast density analyzed using VolparaDensity.  

- VolparaAnalytics assists in quality assurance by monitoring critical elements of the breast imaging process and generating key metrics to help breast imaging centers monitor the performance of technologists, readers, and mammography and tomosynthesis machines. VolparaAnalytics provides unique information such as average pressure applied by each technologist, and breast density profiles by mammography system, helping address potential issues early.

- VolparaDose calculates mammography dose by using a standard mean glandular dose (MGD) algorithm along with patient-specific volumetric breast density to give a better estimate of the dose absorbed by the specific breast. The VolparaDose data can be inserted directly into patient letters on compatible mammography reporting systems, and sent to enterprise wide dose tracking systems.  

For more information: www.volparasolutions.com

Related Content

 Lunit, a leading medical AI software company, will be joining the 106th Radiological Society of North America (RSNA) this year, presenting its AI solutions for chest X-ray and mammography at partner booths.
News | Artificial Intelligence | November 24, 2020
November 24, 2020 — Lunit, a leading medical AI software company, will be joining the 106th...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.